ArticleJournal of cancer research and clinical oncology2019

Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.

Alice Indini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.